ZA200504123B - Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor. - Google Patents

Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor. Download PDF

Info

Publication number
ZA200504123B
ZA200504123B ZA200504123A ZA200504123A ZA200504123B ZA 200504123 B ZA200504123 B ZA 200504123B ZA 200504123 A ZA200504123 A ZA 200504123A ZA 200504123 A ZA200504123 A ZA 200504123A ZA 200504123 B ZA200504123 B ZA 200504123B
Authority
ZA
South Africa
Prior art keywords
phenyl
trifluoro
hmg
propanol
coa reductase
Prior art date
Application number
ZA200504123A
Other languages
English (en)
Inventor
Dwayne Thomas Friesen
David Keith Lyon
Timothy Joseph Mcdermott
Douglas Alan Lorenz
Bruno Caspar Hancock
Ravi Mysore Shanker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32682223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200504123(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200504123B publication Critical patent/ZA200504123B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200504123A 2002-12-20 2005-05-20 Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor. ZA200504123B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43534502P 2002-12-20 2002-12-20

Publications (1)

Publication Number Publication Date
ZA200504123B true ZA200504123B (en) 2006-02-22

Family

ID=32682223

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200504123A ZA200504123B (en) 2002-12-20 2005-05-20 Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor.

Country Status (24)

Country Link
US (1) US7897175B2 (fr)
EP (1) EP1581210B1 (fr)
JP (1) JP2006512359A (fr)
KR (1) KR20050088190A (fr)
CN (1) CN1728995A (fr)
AR (1) AR042534A1 (fr)
AT (1) ATE389396T1 (fr)
AU (1) AU2003286372A1 (fr)
BR (1) BR0317593A (fr)
CA (1) CA2509688A1 (fr)
CO (1) CO5590898A2 (fr)
DE (1) DE60319877T2 (fr)
ES (1) ES2300628T3 (fr)
GT (1) GT200300295A (fr)
IL (1) IL169090A0 (fr)
NL (1) NL1025070C (fr)
NO (1) NO20052779L (fr)
PE (1) PE20040970A1 (fr)
PL (1) PL377606A1 (fr)
RU (1) RU2005119176A (fr)
TW (1) TW200420301A (fr)
UY (1) UY28134A1 (fr)
WO (1) WO2004056359A1 (fr)
ZA (1) ZA200504123B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CZ20033341A3 (cs) * 2001-06-21 2004-10-13 Pfizeráproductsáinc Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
WO2003000226A2 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques contenant des ensembles polymere et medicament
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
EP1819681B1 (fr) * 2004-11-23 2009-08-12 Warner-Lambert Company LLC Derives d'acide 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoique comme inhibiteurs de hmg co-a reductase pour le traitement de l'hyperlipidemie
US20090169583A1 (en) * 2005-02-08 2009-07-02 Pfizer, Inc. Solid Adsorbates of Hydrophobic Drugs
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1893178A1 (fr) 2005-05-31 2008-03-05 Pfizer Products Incorporated Compositions pharmaceutiques d'inhibiteurs de la proteine de transfert d'ester de cholesteryle et d'inhibiteurs de la reductase hmg-coa
JP2009504590A (ja) * 2005-08-08 2009-02-05 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつ剤型
CA2618255C (fr) 2005-08-08 2015-05-26 Abbott Gmbh & Co. Kg Compositions d'itraconazole presentant une biodisponibilite amelioree
DE102005049293A1 (de) * 2005-10-15 2007-04-26 Bayer Healthcare Ag Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
US7351853B2 (en) * 2006-01-23 2008-04-01 Albion Advanced Nutrition Method of manufacturing a granular mineral composition
KR100791256B1 (ko) * 2006-03-17 2008-01-03 주식회사 대웅제약 약학적으로 유용하고 안정한 아토바스타틴 고체분산체 및이를 포함하는 조성물
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
WO2008039894A2 (fr) * 2006-09-27 2008-04-03 Dr. Reddy's Labortories, Ltd. Compositions pharmaceutiques d'atorvastatine
WO2008065506A2 (fr) * 2006-11-29 2008-06-05 Pfizer Products Inc. Compositions pharmaceutiques comprenant des nanoparticules constituées de polymères gastro-résistants et de caséine
AR071706A1 (es) * 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
WO2010075068A1 (fr) 2008-12-16 2010-07-01 Schering Corporation Dérivés de pyridopyrimidine et leurs procédés d'utilisation
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
MX345650B (es) * 2010-11-04 2017-02-09 Hoffmann La Roche Composicion que comprende 2-metilpropanotioato de s- [2 -( [ [1-(2-etilbutil) -ciclohexil] -carbonil]amino) fenil] y croscarmelosa de sodio.
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
AU2015307306B2 (en) * 2014-08-28 2021-01-21 Newamsterdam Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors
JP2019131472A (ja) * 2016-05-31 2019-08-08 興和株式会社 医薬組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
CA2150372C (fr) 1993-01-19 2002-08-20 Nancy L. Mills Composition orale stable de ci-981 et procede de preparation
JPH11506100A (ja) * 1995-06-01 1999-06-02 ジー．ディー．サール アンド カンパニー ミソプロストールの安定化された分散系
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
BRPI9802144B1 (pt) * 1997-05-30 2017-03-28 Ezequiel Mayorga Jorge dispositivo osmótico multicapa aperfeiçoado
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
AU2157400A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
EP1970052A2 (fr) * 1999-02-09 2008-09-17 Pfizer Products Inc. Compositions de médicaments basiques avec une meilleure biodisponibilité
EP1027888B1 (fr) * 1999-02-10 2009-06-10 Pfizer Products Inc. Dispositif osmotique pour délivrer des dispersions solides amorphes des médicaments
ES2215050T3 (es) * 2000-06-09 2004-10-01 Lek Pharmaceutical And Chemical Co. D.D. Composicion estabilizada farmaceuticamente eficaz y formulacion farmaceutica que la comprende.
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CZ2003390A3 (en) * 2000-08-15 2004-03-17 Pfizer Products Inc. Therapeutic combination of a cetp inhibitor and atorvastatin
US20020077348A1 (en) 2000-11-21 2002-06-20 Dean Herbert M. Dosage unit for cardioprotection
US20040235935A1 (en) * 2001-06-12 2004-11-25 Francis Vanderbist Oral pharmaceutical composition containing a statin derivative
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
US20040132771A1 (en) 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

Also Published As

Publication number Publication date
EP1581210B1 (fr) 2008-03-19
DE60319877D1 (de) 2008-04-30
PL377606A1 (pl) 2006-02-06
NO20052779D0 (no) 2005-06-08
NL1025070A1 (nl) 2004-06-22
UY28134A1 (es) 2004-07-30
US20040197398A1 (en) 2004-10-07
KR20050088190A (ko) 2005-09-02
NO20052779L (no) 2005-08-25
BR0317593A (pt) 2005-11-22
PE20040970A1 (es) 2004-12-14
GT200300295A (es) 2004-08-18
AU2003286372A1 (en) 2004-07-14
TW200420301A (en) 2004-10-16
WO2004056359A1 (fr) 2004-07-08
IL169090A0 (en) 2007-07-04
US7897175B2 (en) 2011-03-01
NL1025070C (nl) 2010-04-06
EP1581210A1 (fr) 2005-10-05
RU2005119176A (ru) 2006-01-20
CO5590898A2 (es) 2005-12-30
ATE389396T1 (de) 2008-04-15
JP2006512359A (ja) 2006-04-13
AR042534A1 (es) 2005-06-22
ES2300628T3 (es) 2008-06-16
CA2509688A1 (fr) 2004-07-08
DE60319877T2 (de) 2009-04-30
CN1728995A (zh) 2006-02-01

Similar Documents

Publication Publication Date Title
ZA200504123B (en) Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor.
EP1961419B1 (fr) Formes posologiques comprenant un inhibiteur de CETP et un inhibiteur de HMG-CoA reductase
EP2305217B1 (fr) Prodedé de fabrication de compositions pharmaceutiques comprenant une dispersion amorphe solide des inhibiteurs de la proteine de transfert des esters de cholesterol
KR20060033033A (ko) 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출 및ｈｍｇ-ｃｏａ 리덕타제 억제제의 순간 방출을 제공하는제형
US20120277315A1 (en) Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1474144A1 (fr) Forme posologique a liberation controlee d'une proteine inhibant le transfert du cholesteryl ester
WO2003000294A1 (fr) Compositions pharmaceutiques contenant une dispersion solide d'un medicament peu soluble dans une matrice et d'un polymere ameliorant la solubilite
WO2004056396A1 (fr) Formes posologiques d'inhibiteurs de la proteine de transfert du cholesterol esterifie et d'inhibiteurs de la hmg-coa reductase presentant une efficacite amelioree
MXPA05006566A (es) Formas de dosificacion que comprenden un inhibidor de la proteina de transferencia de esteres de colesterilo y un inhibidor de la 3-hidroxi-3-metilglutaril-coenzima a-reductasa.
AU2003201713A1 (en) Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor